



What's New

27.02.2018

DoP Invokes Para 3 of DPCO, 2013 under acute shortage of formulation Viraferonpeg 100 mcg Injection

Department of Pharmaceuticals (DOP) has invoked the powers under Section 3 of Drug Price Control Order (DPCO) and directed Fulford India Limited to continue to maintain same level of production and availability as during Nov, 2013 to Nov, 2015 of ViraferonPeg 100 mcg injection.

DOP has cited acute shortage of ViraferonPeg, a prescription drug used primarily for treating chronic hepatitis B and C infections, multiple myeloma, follicular lymphoma and hairy cell leukemia.

The drug manufacturer is ordered to maintain the same level of production and availability as during November 2013- 2015. It should also submit a weekly report alongwith production plan for the next week to National Pharmaceutical Pricing Authority (NPPA) and DOP.

This order will be valid for 3 (three) months.

NPPA will recommend withdrawal or extension as the case may be, two weeks before the expiry of the period.

Para 3 of DPCO 2013 empowers the government to direct any manufacturer of any active pharmaceutical ingredient or bulk drug or formulation to increase the production and to sell such active pharmaceutical ingredient or bulk drug to such other manufacturer(s) of formulations and to direct formulators to sell the formulations to institutions, hospitals or any agency in order to achieve adequate availability and to regulate the distribution of drugs, in case of emergency or in circumstances of urgency or in case of non-commercial use in public interest.

It also empowers to the Government to call for such information from manufacturers of active pharmaceutical ingredients or bulk drugs or formulations, as it may consider necessary and such manufacturer shall furnish the required information within such time the Government may fix.

Click the following links for Notifications

[DoP Invokes Para 3 of DPCO, 2013 under acute shortage of formulation Viraferonpeg 100 mcg Injection](#)